Field & Main Bank Takes $2.70 Million Position in AbbVie Inc. $ABBV

Key Points

• Field & Main Bank acquired a new $2.70 million position in AbbVie during the second quarter, purchasing 10,715 shares. Institutional investors collectively own 70.23% of the company.
• Analyst sentiment remains positive, with AbbVie carrying a consensus “Moderate Buy” rating and an average price target of $275.95, above its reported $256.27 share price.
• AbbVie exceeded quarterly earnings and revenue expectations and pays a $1.73 quarterly dividend, though Humira’s declining sales and an insider’s $8.18 million stock sale remain potential concerns.

Field & Main Bank purchased a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,715 shares of the company's stock, valued at approximately $2,696,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Prosperitas Financial LLC grew its holdings in AbbVie by 13.5% during the 2nd quarter. Prosperitas Financial LLC now owns 22,314 shares of the company's stock valued at $5,615,000 after buying an additional 2,650 shares during the last quarter. Pin Oak Investment Advisors Inc. acquired a new stake in shares of AbbVie during the second quarter valued at $613,000. 49 Wealth Management LLC purchased a new stake in AbbVie during the 2nd quarter worth about $2,729,000. Livforsakringsbolaget Skandia Omsesidigt increased its position in AbbVie by 7.6% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 167,270 shares of the company's stock worth $42,018,000 after purchasing an additional 11,800 shares in the last quarter. Finally, Rakuten Investment Management Inc. raised its stake in AbbVie by 10.2% in the 2nd quarter. Rakuten Investment Management Inc. now owns 289,091 shares of the company's stock valued at $73,519,000 after purchasing an additional 26,793 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ABBV shares. Wall Street Zen lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 5th. Wolfe Research raised shares of AbbVie from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective for the company in a research report on Thursday, August 13th. Bank of America upped their price objective on shares of AbbVie from $234.00 to $276.00 and gave the company a "buy" rating in a research note on Friday, July 10th. Evercore set a $235.00 price target on AbbVie in a report on Friday, May 15th. Finally, Canaccord Genuity Group increased their price target on AbbVie from $282.00 to $290.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $275.95.

AbbVie Stock Down 0.1%

NYSE:ABBV opened at $256.27 on Monday. The company has a market cap of $452.78 billion, a P/E ratio of 72.39, a P/E/G ratio of 1.16 and a beta of 0.29. The firm's 50 day moving average is $254.66 and its two-hundred day moving average is $230.05. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business's quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio is 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.06% of the company's stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source